Cardiorentis AG is a privately owned biopharmaceutical company designed for the new world of drug development. Focused, fast moving and flexible, with patients at its heart, Cardiorentis AG is committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases.
Cardiorentis AG fuses superior science and pharmaceutical intelligence, offering a company with a genuine thirst for scientific advancement, but with the practical know-how to be able to bring products to the market and enhance the lives of patients. With a notable expertise in cardiology, Cardiorentis AG is initially concentrating its efforts on ularitide for the treatment of acute cardiovascular indications, with the aim of developing the first evidence-based drug treatment for acute heart failure (AHF).
Cardiorentis AG is proud of the strong partnerships it has built with academic researchers, universities and practicing clinicians across the world; all working closely together to drive important research forward. United by our common goal, we believe that our actions today will shape the future of patient care tomorrow.
Cardiorentis AG was founded in 2010 and acquired CardioPep Pharma GmbH of Hannover, Germany. Cardiorentis AG is based in Zug Switzerland.
Cardiorentis AG is a privately funded biopharmaceutical company. All of the individual investors have a heritage and knowledge in scientific discovery, the pharmaceutical industry. For all investor relations enquiries please contact email@example.com